《美股業績》BioNTech(BTNX.US)次季轉虧1.9億歐元 削藥物研發預算
BioNTech(BNTX.US)公布,今年第二季收入按年由32億歐元(下同)大降至1.68億元,遠低於市場預期的6.92億元;季度虧損1.9億元,對比去年同期為錄盈利16.7億元;每股虧損0.79元,好於市場預期的虧損0.92元。
由於新冠疫情退卻導致疫苗需求減少,從而影響收入,公司削減今年藥物研發預算,最新料介乎20億元至22億元,低於早前預測的24億元至26億元。
BioNTech又重申,今年新冠疫苗收入預計將約50億元,低於去年的172億元,估計秋季的疫苗接種活動將再次推動銷售增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.